Last November, the FDA released an Emergency Use Authorization (EUA) for the use of monoclonal antibody therapy for adult and pediatric patients with mild to moderate COVID-19. Currently, there is some confusion about the availability and access issues to these treatment options.

In this episode, part two of a three-part series, we will address questions and concerns about the distribution and availability of these therapies.

Guest speakers:
Azra Behlim, PharmD, MBA
Senior Director
Pharmacy Sourcing and Program Services 
Vizient

Steve Rudner, PharmD, MS
Director
Pharmacy Network Contracting
Vizient

Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Associate Vice President
Clinical Resources
Vizient

Show Notes:
[02:05] Access to the monoclonal antibody therapies
[03:51] No lack of supply
[05:07] Infusion options
[09:59] Misconceptions and challenges around distribution
[11:40] Every idea worth exploring

Links | Resources:

Press release and information from FDA Click here

Information from FDA on EUA for monoclonal antibody therapy Click here

ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here

[ For more information, contact: ASPRstakeholder@HHS.gov ]

JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here

Subscribe Today!

Apple Podcasts

Spotify

Android

Google Podcasts

Stitcher

RSS Feed